Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Soleno Therapeutics (SLNO) Preferred Stock Liabilities (2016)

Soleno Therapeutics (SLNO) has disclosed Preferred Stock Liabilities for 4 consecutive years, with $13.0 as the latest value for Q4 2016.

  • On a quarterly basis, Preferred Stock Liabilities rose 160.0% to $13.0 in Q4 2016 year-over-year; TTM through Dec 2016 was $13.0, a 160.0% increase, with the full-year FY2016 number at $13.0, up 160.0% from a year prior.
  • Preferred Stock Liabilities was $13.0 for Q4 2016 at Soleno Therapeutics, up from $5.0 in the prior quarter.
  • In the past five years, Preferred Stock Liabilities ranged from a high of $1.5 million in Q4 2013 to a low of $5.0 in Q4 2015.
  • A 4-year average of $750004.5 and a median of $750006.5 in 2013 define the central range for Preferred Stock Liabilities.
  • Biggest YoY gain for Preferred Stock Liabilities was 160.0% in 2016; the steepest drop was 160.0% in 2016.
  • Soleno Therapeutics' Preferred Stock Liabilities stood at $1.5 million in 2013, then changed by 0.0% to $1.5 million in 2014, then crashed by 100.0% to $5.0 in 2015, then skyrocketed by 160.0% to $13.0 in 2016.
  • Per Business Quant, the three most recent readings for SLNO's Preferred Stock Liabilities are $13.0 (Q4 2016), $5.0 (Q4 2015), and $1.5 million (Q3 2014).